Benzofuran compounds which contain at least one detectable label selected from the group consisting of <SUP>131</SUP>I, <SUP>123</SUP>I, <SUP>124</SUP>I<SUP>, 125</SUP>I, <SUP>76</SUP>Br, <SUP>75</SUP>Br, <SUP>18</SUP>F, <SUP>19</SUP>F, <SUP>11</SUP>C, <SUP>13</SUP>C, <SUP>14</SUP>C and <SUP>3</SUP>H are provided as amyloid imaging agents for detecting brain amyloid deposits as well as other amyloidogenic peptides associated with systemic or localized amyloidosis. Additionally, the compounds are useful for determining if patients, presenting with clinically confusing cases of dementia or presenting with mild cognitive impairment, have Alzheimer's disease. The compounds are additionally useful as surrogate markers for monitoring the efficacy of anti-amyloidosis therapies.
ISOTOPICALLY-LABELED BENZOFURAN COMPOUNDS AS IMAGINGAGENTS FOR AMYLOIDOGENIC PROTEINS